search
Back to results

Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation

Primary Purpose

Prematurity, Respiratory Failure, Ventilator Lung; Newborn

Status
Completed
Phase
Not Applicable
Locations
Saudi Arabia
Study Type
Interventional
Intervention
NI-NAVA
NIPPV
Sponsored by
King Fahad Armed Forces Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prematurity focused on measuring Non-invasive Neurally Adjusted Ventilatory Assist NI-NAVA, Nasal Intermittent Positive Pressure Ventilation NIPPV, post extubation

Eligibility Criteria

undefined - 2 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Born less than 32 weeks gestation with respiratory distress syndrome (RDS) and requiring endotracheal tube and mechanical ventilation.
  2. Less than two weeks old
  3. First extubation attempt
  4. CRIB score 0-5
  5. Written-informed parental consent for the study

Exclusion Criteria:

  1. Major congenital malformations or respiratory abnormalities
  2. Neuromuscular disease
  3. phrenic nerve palsy
  4. Intraventricular hemorrhage (IVH) grade III or IV
  5. Absence of informed consent
  6. Out born infants

Sites / Locations

  • King Fahad Armed Forces Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

NI-NAVA

NIPPV

Arm Description

Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum < 5 for 72 hours post extubation

Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation

Outcomes

Primary Outcome Measures

Treatment failure
Treatment failure during the first 72 hours post-extubation. Reintubation (failure of extubation) within 72 hours' post extubation. Treatment failure is defined as: Hypoxia (FiO 2 requirement > 0.35) Respiratory acidosis defined as pH < 7.2 & PCo2> 60 mmHg Major apnea requiring mask ventilation or > 4 episodes/ hour. The protocol will discontinue according to treatment failure criteria as mentioned above. Rescue treatment with NIPPV will be allowed and will be considered as treatment failure

Secondary Outcome Measures

Death prior to discharge
Death
Intraventricular haemorrhage IVH (grades III & IV)
defined as haemorrhage causing ventricular dilatation with or without brain parenchymal involvement
Pneumothorax
diagnosed radiologically
Bronchopulmonary dysplasia (BPD)
defined as requirement for supplemental oxygen at 28 days of life or requirement for supplemental oxygen at 36 weeks' postmenstrual age
Necrotizing enterocolitis
defined according to modified Bell's criteria (stage 2 to 3)
Gastrointestinal perforation
diagnosed radiologically or at operation
Nosocomial sepsis
defined as positive blood or cerebrospinal fluid (CSF) cultures taken after five days of age
Retinopathy of prematurity (ROP)
stage 3 or greater (International classification)
Duration of hospitalisation or Length of stay (in days)
Number of days in hospital until first discharge

Full Information

First Posted
December 16, 2017
Last Updated
July 25, 2021
Sponsor
King Fahad Armed Forces Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03388437
Brief Title
Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation
Official Title
Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation: A Randomised Control Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
May 1, 2017 (Actual)
Primary Completion Date
April 30, 2019 (Actual)
Study Completion Date
April 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King Fahad Armed Forces Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Non-invasive respiratory support has been emerging in the management of respiratory distress syndrome (RDS) in preterm infants to minimise the risk of lung injury. Intermittent positive pressure ventilation (NIPPV) provides a method of augmenting continuous positive airway pressure (CPAP) by delivering ventilator breaths via nasal prongs.It may increase tidal volume, improve gas exchange and reduce work of breathing. However, NIPPV may associate with patient-ventilator asynchrony that can cause poor tolerance and risk of intubation. It may also in increased risk of pneumothorax and bowel perforation because of increase in intrathoracic pressure. On the other hand, neurally adjusted ventilatory assist (NAVA) is a newer mode of ventilation, which has the potential to overcome these challenges. It uses the electrical activity of the diaphragm (EAdi) as a signal to synchronise the mechanical ventilatory breaths and deliver an inspiratory pressure based on this electrical activity. Comparing NI-NAVA and NIPPV in preterm infants, has shown that NI-NAVA improved the synchronization between patient and ventilator and decreased diaphragm work of breathing . There is lack of data on the use of NI-NAVA in neonates post extubation in the literature. To date, no study has focused on short-term impacts. Therefore, it is important to evaluate the need of additional ventilatory support post extubation of NI-NAVA and NIPPV and also the risk of developing adverse outcomes. Aim: The aim is to compare NI-NAVA & NIPPV in terms of extubation failure in infants< 32 weeks gestation. Hypothesis: Investigators hypothesized that infants born prematurely < 32 weeks gestation who extubated to NI-NAVA have a lower risk of extubation failure and need of additional ventilatory support.
Detailed Description
Study Design: Randomised controlled trial Study Setting: single center NICU level III, KFAFH tertiary care center , Jeddah Saudi Arabia

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prematurity, Respiratory Failure, Ventilator Lung; Newborn
Keywords
Non-invasive Neurally Adjusted Ventilatory Assist NI-NAVA, Nasal Intermittent Positive Pressure Ventilation NIPPV, post extubation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomised controlled trial A web generated a block randomisation list. A block of 4, stratification based on GA, gender & antenatal steriods Sequentially numbered, opaque and sealed envelopes Restricted access to envelopes
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NI-NAVA
Arm Type
Experimental
Arm Description
Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum < 5 for 72 hours post extubation
Arm Title
NIPPV
Arm Type
Active Comparator
Arm Description
Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation
Intervention Type
Device
Intervention Name(s)
NI-NAVA
Intervention Description
Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision. The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter & positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation
Intervention Type
Device
Intervention Name(s)
NIPPV
Intervention Description
Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision. The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter & positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation
Primary Outcome Measure Information:
Title
Treatment failure
Description
Treatment failure during the first 72 hours post-extubation. Reintubation (failure of extubation) within 72 hours' post extubation. Treatment failure is defined as: Hypoxia (FiO 2 requirement > 0.35) Respiratory acidosis defined as pH < 7.2 & PCo2> 60 mmHg Major apnea requiring mask ventilation or > 4 episodes/ hour. The protocol will discontinue according to treatment failure criteria as mentioned above. Rescue treatment with NIPPV will be allowed and will be considered as treatment failure
Time Frame
72 hours
Secondary Outcome Measure Information:
Title
Death prior to discharge
Description
Death
Time Frame
90 days from birth
Title
Intraventricular haemorrhage IVH (grades III & IV)
Description
defined as haemorrhage causing ventricular dilatation with or without brain parenchymal involvement
Time Frame
7 days after extubation
Title
Pneumothorax
Description
diagnosed radiologically
Time Frame
7 days after extubation
Title
Bronchopulmonary dysplasia (BPD)
Description
defined as requirement for supplemental oxygen at 28 days of life or requirement for supplemental oxygen at 36 weeks' postmenstrual age
Time Frame
36 weeks' postmenstrual age
Title
Necrotizing enterocolitis
Description
defined according to modified Bell's criteria (stage 2 to 3)
Time Frame
7 days after extubation
Title
Gastrointestinal perforation
Description
diagnosed radiologically or at operation
Time Frame
7 days after extubation
Title
Nosocomial sepsis
Description
defined as positive blood or cerebrospinal fluid (CSF) cultures taken after five days of age
Time Frame
7 days after extubation
Title
Retinopathy of prematurity (ROP)
Description
stage 3 or greater (International classification)
Time Frame
40 weeks corrected postnatal age
Title
Duration of hospitalisation or Length of stay (in days)
Description
Number of days in hospital until first discharge
Time Frame
From admission to first discharge from hospital, assessed up to 6 months

10. Eligibility

Sex
All
Maximum Age & Unit of Time
2 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Born less than 32 weeks gestation with respiratory distress syndrome (RDS) and requiring endotracheal tube and mechanical ventilation. Less than two weeks old First extubation attempt CRIB score 0-5 Written-informed parental consent for the study Exclusion Criteria: Major congenital malformations or respiratory abnormalities Neuromuscular disease phrenic nerve palsy Intraventricular hemorrhage (IVH) grade III or IV Absence of informed consent Out born infants
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raniah Aljeaid
Organizational Affiliation
King Fahad Armed Forces Hospital Jeddah
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nisreen Kafi
Organizational Affiliation
King Fahad Armed Forces Hospital Jeddah
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Fawzia Sabbagh
Organizational Affiliation
King Fahad Armed Forces Hospital Jeddah
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mai Abu Seoud
Organizational Affiliation
King Fahad Armed Forces Hospital Jeddah
Official's Role
Study Chair
Facility Information:
Facility Name
King Fahad Armed Forces Hospital
City
Jeddah
ZIP/Postal Code
21159
Country
Saudi Arabia

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
26178463
Citation
Lee J, Kim HS, Jung YH, Shin SH, Choi CW, Kim EK, Kim BI, Choi JH. Non-invasive neurally adjusted ventilatory assist in preterm infants: a randomised phase II crossover trial. Arch Dis Child Fetal Neonatal Ed. 2015 Nov;100(6):F507-13. doi: 10.1136/archdischild-2014-308057. Epub 2015 Jul 15.
Results Reference
result
PubMed Identifier
22137670
Citation
Stein H, Howard D. Neurally adjusted ventilatory assist in neonates weighing <1500 grams: a retrospective analysis. J Pediatr. 2012 May;160(5):786-9.e1. doi: 10.1016/j.jpeds.2011.10.014. Epub 2011 Dec 3.
Results Reference
result

Learn more about this trial

Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation

We'll reach out to this number within 24 hrs